**Cover letter**

I would like to present an article entitled "Expression of immune checkpoints in patients with prostate cancer". It presents the results of the study which the aim was to assess the level of PD-1, PD-L1 and CTLA-4 expression on peripheral blood mononuclear cells of patients with primary prostate cancer and to demonstrate their applicability in clinical practice. The results of the study indicate that the evaluation of PD-1 and PD-L1 expression on peripheral blood mononuclear cells can be used in clinical practice and serve as a prognostic and predictive biomarker in prostate cancer. This article presents the results of the original study. It has not been previously published and has not been submitted for publication elsewhere while it is being considered. This manuscript has been approved by all co-authors, as well as by the responsible authorities at the institution where the work has been carried out. Authors agrees to the automatic and free copyright transfer to the Publisher, if and when the work is accepted for publication. Authors agrees to the automatic and free copyright transfer to the Publisher, if and when the work is accepted for publication. All sources of financial support have been fully disclosed. Authors confirms that they are familiar with and will observe the Editorial Policy and Information for Authors included in "Oncology in Clinical Practice". Authors agrees to accept appropriate invoice from the Publisher in case colour illustrations are implemented (100 USD per page).